Tumour calcifications as a prognostic marker in glioblastoma patients treated with bevacizumab
Purpose: Glioblastoma (GBM) is the most common and lethal malignant primary brain tumor in adults and its prognosis remains very poor. Bevacizumab (BV) is an anti-angiogenic drug widely used in recurrent GBM. BV can induce GBM calcifications and some authors identified a possible correlation between...
| Autor principal: | |
|---|---|
| Formato: | masterThesis |
| Idioma: | eng |
| Publicado em: |
2022
|
| Assuntos: | |
| Texto completo: | https://hdl.handle.net/10216/142161 |
| País: | Portugal |
| Oai: | oai:repositorio-aberto.up.pt:10216/142161 |